Autoimmune disease

Monoclonal antibody
#Autoimmune disease #ImmunAbs #Monoclonal antibodies #Phase I trial

C5-targetting monoclonal antibody clears Phase I trials

Biotechnology company ImmunAbs has announced the successful completion of a Phase I clinical trial for IM-101, a humanised monoclonal antibody targeting complement C5. The complement system is widely acknowledged for its critical involvement in autoimmune diseases. The randomised, double-blind, placebo-controlled trial was conducted to… Read More

#News

#AnaMar #Autoimmune disease #European Medicines Agency #FDA #Fibrotic disease #Orphan drugs

Dual-action treatment for fibrotic disease secures orphan drug status

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and in vivo models of… Read More

#News #Regulatory

#Autoimmune disease #Biologics / Biotechnology #COUR Pharmaceuticals #Financing #Investment

$105 million raised to support therapies for autoimmune diseases

COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures. The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials. The Roche Venture Fund,… Read More

#Business & Investment #News

Clinical trial
#Autoimmune disease #Clinical trial #Phase II trial #Vera Therapeutics

Drug shows disease-modifying effect in IgA nephropathy

Vera Therapeutics has announced positive 72-week data from the open label extension (OLE) period of its Phase IIb ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in… Read More

#News

Medical laboratory
#Annexon #Autoimmune disease #Phase I trial #Small molecules

Positive Phase I results for small molecule complement inhibitor

Biopharmaceutical company Annexon has reported promising results from its Phase I single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502. ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway… Read More

#News

Scleroderma
#Autoimmune disease #Certa Therapeutics #Clinical trial #Dermatology #Phase II trial

Scleroderma drug trial shows up to 60% improvement

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The results were presented at ACR Convergence 2023, the annual scientific meeting of the American College of Rheumatology in San Diego, California (10-15 November 2023). Treatment… Read More

#News

#Autoimmune disease #Axcella Therapeutics #Chronic Fatigue Syndrome #Covid-19 #Long Covid

Long Covid: A call to action for drug developers

According to the National Institutes for Health, some form of long Covid affects around 10% of people infected with Covid-19, with fatigue being the most common symptom. Despite the size of the market and the global impact, there are currently no effective treatments. Diana Spencer caught up with Bill Hinshaw,… Read More

#Exclusive Content

Monoclonal antibodies
#AbolerIS Pharma #Arthritis #Autoimmune disease #Financing #Monoclonal antibodies

€27.3M to advance monoclonal antibody for autoimmune diseases

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases. Read More

#Business & Investment #News

Antibodies
#Antibodies #Autoimmune disease #Collaboration #Ono Pharmaceutical #Twist Bioscience

Partners to discover antibodies for autoimmune diseases

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono. Twist also recently… Read More

#Business & Investment #News

Antibody
#Acute inflammatory conditions #Antibody #Autoimmune disease #Biologics

Novel antibody displays potent anti-inflammatory activity

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F… Read More

#News

Subcutaneous injection
#Antibody #Autoimmune disease #Drug delivery #FDA #Halozyme #Phase III trial

FDA approves subcutaneous injectable for myasthenia gravis

The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart Hytrulo is a… Read More

#News #Regulatory

Blood cells
#Autoimmune disease #Biotechnology #Haemodialysis #Invizius

‘Angry Blood’ haemodialysis study recruits its 300th patient 

Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, has recruited its 300th patient to the ‘Angry Blood’ study.   This is a significant milestone in its novel kinetic study to identify patients with elevated complement responses… Read More

#News

Innovation
#Advanced Therapies #Animal models #Autoimmune disease #Cell and gene therapy #Data #Genetics / genomics #Immunology #Pharma

New podcast on animal genomics, immunology and CGTs

This is the latest episode of the free DDW narrated podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find… Read More

#News

Handshake
#Autoimmune disease #Collaboration #License agreement #Tay Therapeutics #VYNE Therapeutics

Tay licenses oral BET inhibitor to VYNE Therapeutics

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021. The out-licensing of both of Tay… Read More

#Business & Investment #News

Arthritis
#Animal models #Arthritis #Autoimmune disease #Immune response #Immune system #University of Southern California

‘Regenerative’ osteoarthritis drug moves to clinical trial

A team of researchers at the Keck School of Medicine of University of Southern California (USC) have found a drug with the potential for curbing painful hyperinflammation from osteoarthritis, according to results of an animal study. The findings indicate that a drug compound, R805/CX-011, may modulate… Read More

#Editor's Choice #News

Treg cells
#Autoimmune disease #Collaboration #Partnership #Regeneron Pharmaceuticals #Sonoma Biotherapeutics #T cell activation

Companies combine efforts on Treg therapies for autoimmune diseases

Sonoma Biotherapeutics and Regeneron Pharmaceuticals have announced plans to collaborate on the discovery, development and commercialisation of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s VelociSuite technologies for the discovery and characterisation of fully human antibodies and T cell… Read More

#News